No Data
No Data
SciSparc- Clearmind Collaboration Evolves With New International Patent Application for Preventing and Treating Depression
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
SciSparc Announces MitoCareX Unveils Groundbreaking Discovery Of Small Molecule Structure In Anti-Cancer Research
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficientlyTEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company"
TLRY, ACB and CGC Are Among Pre Market Gainers
SciSparc Granted Another Patent, Strengthening Its Core Technology in Canada
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders
SciSparc Achieves Major Milestone With First Patient Dosed in Autism Spectrum Disorder Clinical Trial
First patient has been dosed in the randomized, controlled, double blind clinical trial for Autism Spectrum Disorder in pediatric patients
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Welcome to a new episode of our Benzinga Psychedelics Podcast. We are joined herein by executives of Clearmind Medicine (NASDAQ:CMND), a biotech company developing a proprietary, psychoactive yet non-
No Data